Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Investigational new drugs

• Publication date

  2013-02-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-013-9937-8PMID 23443507PMCID PMC3723766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

  2012cited by this paper
• Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.

  2012cited by this paper
• Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

  2012cited by this paper
• Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B‐precursor acute lymphoblastic leukemia

  2012cited by this paper
• The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

  2012cited by this paper
• Targeting mTOR for the treatment of AML. New agents and new directions

  2011cited by this paper
• Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

  2011cited by this paper
• Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

  2011cited by this paper
• Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

  2011cited by this paper
• Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia

  2010cited by this paper
• Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

  2010cited by this paper
• Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

  2010cited by this paper
• A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

  2009cited by this paper
• The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T- cell acute lymphoblastic leukemia: A report from the Children's Oncology Group

  2009cited by this paper
• Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

  2009cited by this paper
• The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia

  2009cited by this paper
• High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

  2009cited by this paper
• The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.

  2009cited by this paper
• Gab2 Is Involved in Differential Phosphoinositide 3-Kinase Signaling by Two Splice Forms of c-Kit*

  2008cited by this paper
• Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

  2008cited by this paper
• Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.

  2008cited by this paper
• A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

  2008cited by this paper
• Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

  2007cited by this paper
• Targeting Checkpoint Kinase 1 in Cancer Therapeutics

  2007cited by this paper
• Phase I and Pharmacokinetic Study of 7-Hydroxystaurosporine and Carboplatin in Advanced Solid Tumors

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

  2006cited by this paper
• Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

  2006cited by this paper
• Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.

  2005cited by this paper
• Antileukemic activity of rapamycin in acute myeloid leukemia.

  2005cited by this paper
• Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways

  2005cited by this paper
• AKT/PKB signaling mechanisms in cancer and chemoresistance.

  2005cited by this paper
• The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01–Induced Apoptosis in Human Multiple Myeloma Cells

  2005cited by this paper
• Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias.

  2005cited by this paper
• A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

  2004cited by this paper
• Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.

  2004cited by this paper
• In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines

  2004cited by this paper
• Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia

  2004cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Survival of acute myeloid leukemia cells requires PI3 kinase activation.

  2003cited by this paper
• Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.

  2002cited by this paper
• Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)

  2002cited by this paper
• Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.

  2001cited by this paper
• A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.

  2000cited by this paper
• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  2000cited by this paper
• D-21266, a new heterocyclic alkylphospholipid with antitumour activity.

  1997cited by this paper
• UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities.

  1989cited by this paper
• UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation.

  1989cited by this paper

• Development and Clinical Applications of PI3K/AKT/mTOR Pathway Inhibitors as a Therapeutic Option for Leukemias.

  2024cites this paper
• Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors

  2023cites this paper
• Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response

  2023cites this paper
• AKT inhibition interferes with the expression of immune checkpoint proteins and increases NK-induced killing of HL60-AML cells

  2023cites this paper
• Synthesis and Antitumor Activity of Staurosporine Derivatives

  2022cites this paper
• Rediscovery of Traditional Plant Medicine: An Underestimated Anticancer Drug of Chelerythrine

  2022cites this paper
• Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia

  2021cites this paper
• Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

  2021cites this paper
• Clinical and Molecular Differentiation Between Malignant Rhabdoid Tumor of the Kidney and Normal Tissue: A Two-Case Report

  2021cites this paper
• Dual Gene Delivery Reagents From Antiproliferative Alkylphospholipids for Combined Antitumor Therapy

  2020cites this paper
• Role of Cell Cycle Control, Checkpoints, and DNA Repair Mechanisms in Stem Cells and Changes with Aging and Cancerogenesis

  2020cites this paper
• The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors

  2020cites this paper
• Targeting the phosphatidylinositol 3-kinase signaling pathway in acute myeloid leukemia

  2020cites this paper
• Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception†

  2020cites this paper
• ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.

  2020cites this paper
• The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells

  2020cites this paper
• PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.

  2019cites this paper
• PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.

  2019cites this paper
• The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme

  2019cites this paper
• Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy.

  2019cites this paper
• The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.

  2019cites this paper
• Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy.

  2019cites this paper
• STK3 is a therapeutic target for a subset of acute myeloid leukemias

  2018cites this paper
• Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

  2018cites this paper
• Analysis and Prospect of Targeted Therapy for Head and Neck Tumors

  2018cites this paper
• Role of Cell Cycle Control, Checkpoints and DNA Repair Mechanisms in Stem Cells and Changes with Aging and Cancerogenesis

  2018cites this paper
• Exploring Structural and Functional Properties of Marburg Virus Matrix Protein-VP40

  2018cites this paper
• The role of AMPK/mTOR modulators in therapy of acute myeloid leukemia.

  2018cites this paper
• Design, Synthesis, and Biological Evaluation of 1,4-Bis(2,3-dihydro-5-oxopyrrol-4-yl)-1,3-butadienes as Potential Chk1 Inhibitors

  2017cites this paper
• Maximising the potential of AKT inhibitors as anti‐cancer treatments

  2017cites this paper
• Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.

  2017cites this paper
• Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model

  2017cites this paper
• Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma

  2016cites this paper
• Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy

  2016cites this paper
• ATM Mutations in Cancer: Therapeutic Implications

  2016cites this paper
• Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.

  2016cites this paper
• Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs.

  2015cites this paper
• Molecular Pathways in Childhood Acute Lymphoblastic Leukemia: From the Bench to the Bedside

  2015cites this paper
• Genome wide expression analysis of radiation-induced DNA damage responses in isogenic HCT116 p53+/+ and HCT116 p53−/− colorectal carcinoma cell lines

  2015cites this paper
• Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

  2015cites this paper
• Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia

  2015cites this paper
• Investigation of the Lipid Binding Properties of the Marburg Virus 3

  2015cites this paper
• Targeting the PI3 Kinase-mTOR Signaling Pathway in AML

  2015cites this paper
• Development of Drugs Targeting the PI3K Signalling Pathway in Leukaemias and Lymphomas

  2015cites this paper
• PI3K/AKT/mTOR信号通路抑制剂在白血病治疗中的研究进展

  2015cites this paper
• [Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway].

  2015cites this paper
• Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

  2015cites this paper
• Investigation of the Lipid Binding Properties of the Marburg Virus Matrix Protein VP40

  2015cites this paper
• Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms

  2015cites this paper
• Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

  2015cites this paper
• Targeting the Mitotic Catastrophe Signaling Pathway in Cancer

  2015cites this paper
• Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy

  2015cites this paper
• CCR New Strategies New Strategies in Acute Myelogenous Leukemia : Leukemogenesis and Personalized Medicine

  2014cites this paper
• Development of Synthetic Lethality Anticancer Therapeutics

  2014cites this paper
• New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine

  2014cites this paper
• Selective anti-cancer agents as anti-aging drugs

  2013cites this paper